206 related articles for article (PubMed ID: 35983558)
1. Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma.
Chen F; Qiu L; Mu Y; Sun S; Yuan Y; Shang P; Ji B; Wang Q
Front Surg; 2022; 9():893372. PubMed ID: 35983558
[TBL] [Abstract][Full Text] [Related]
2. The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study.
Yin GQ; Li ZL; Li D
Cancer Manag Res; 2022; 14():2133-2141. PubMed ID: 35795828
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study.
Zhou RQ; Luo J; Li LJ; Du M; Wu QC
BMC Surg; 2023 May; 23(1):114. PubMed ID: 37161374
[TBL] [Abstract][Full Text] [Related]
6. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study).
Yang Y; Zhu L; Cheng Y; Liu Z; Cai X; Shao J; Zhang M; Liu J; Sun Y; Li Y; Yi J; Yu B; Jiang H; Chen H; Yang H; Tan L; Li Z
BMC Cancer; 2022 May; 22(1):506. PubMed ID: 35524205
[TBL] [Abstract][Full Text] [Related]
7. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
[TBL] [Abstract][Full Text] [Related]
8. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
[TBL] [Abstract][Full Text] [Related]
9. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.
Yang G; Su X; Huang Y; Luo G; Wang Z; Cai P; Zheng Y; Bei T; Huang M; Bai Y; He H; Xiang J; Cai M; Zhong J; Guo Q; Zhang X
J Transl Med; 2023 Jun; 21(1):411. PubMed ID: 37355621
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
Yang G; Su X; Yang H; Luo G; Gao C; Zheng Y; Xie W; Huang M; Bei T; Bai Y; Wang Z; Cai P; He H; Xiang J; Cai M; Zhang Y; Qu C; Fu J; Liu Q; Hu Y; Zhong J; Huang Y; Guo Q; Zhang X
Ann Transl Med; 2021 Aug; 9(15):1254. PubMed ID: 34532391
[TBL] [Abstract][Full Text] [Related]
11. M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: A pilot study.
Wang S; Xu G; Li M; Zheng J; Wang Y; Feng X; Luo J; Wang S; Liu H; Duan W; Zhang H; Huang D; Zhao F; Nie Y; Yang J
Front Oncol; 2023; 13():1139990. PubMed ID: 36969032
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
Liu J; Yang Y; Liu Z; Fu X; Cai X; Li H; Zhu L; Shen Y; Zhang H; Sun Y; Chen H; Yu B; Zhang R; Shao J; Zhang M; Li Z
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338088
[TBL] [Abstract][Full Text] [Related]
13. Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
Liu J; Zhu L; Huang X; Lu Z; Wang Y; Yang Y; Ye J; Gu C; Lv W; Zhang C; Hu J
J Cancer Res Clin Oncol; 2024 Mar; 150(3):161. PubMed ID: 38536527
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy sensitizes locally advanced esophageal squamous cell carcinoma to PD-1 blockade for a higher pathological complete response rate and survival.
Wang P; Lei M; Weng G; Huang R; Lin H; Wei W; Chen Y; He H; Chen P; Zhang D; Chen W; Zhou H; Gao P; Liu S; Wang F
Transl Oncol; 2023 Oct; 36():101736. PubMed ID: 37478670
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol.
Chen M; Huang Y; Zhang S; Zeng T; Huang G; Chen C; Zheng B
Trials; 2023 Aug; 24(1):554. PubMed ID: 37626367
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.
Liu J; Li J; Lin W; Shao D; Depypere L; Zhang Z; Li Z; Cui F; Du Z; Zeng Y; Jiang S; He P; Gu X; Chen H; Zhang H; Lin X; Huang H; Lv W; Cai W; Liang W; Liang H; Jiang W; Wang W; Xu K; Cai W; Wu K; Lerut T; Fu J; He J
Int J Cancer; 2022 Jul; 151(1):128-137. PubMed ID: 35188268
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study.
Xia P; Li P; Wu S; Wang Y; Ye P; Zhang C; Hu J; Kidane B; Lampridis S; Velotta JB; Wakefield CJ; Zhu L; Wang L
Ann Transl Med; 2022 Sep; 10(18):991. PubMed ID: 36267734
[TBL] [Abstract][Full Text] [Related]
18. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
Front Immunol; 2022; 13():853922. PubMed ID: 35720312
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy.
Xu L; Qi Y; Jiang Y; Ji Y; Zhao Q; Wu J; Lu W; Wang Y; Chen Q; Wang C
Ann Transl Med; 2022 Mar; 10(6):325. PubMed ID: 35433940
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
Yang W; Xing X; Yeung SJ; Wang S; Chen W; Bao Y; Wang F; Feng S; Peng F; Wang X; Chen S; He M; Zhang N; Wang H; Zeng B; Liu Z; Kidane B; Seder CW; Koyanagi K; Shargall Y; Luo H; Peng S; Cheng C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]